Cosmological Non-Linearities as an Effective Fluid

The universe is smooth on large scales but very inhomogeneous on small scales. Why is the spacetime on large scales modeled to a good approximation by the Friedmann equations? Are we sure that small-scale non-linearities do not induce a large backreaction? Related to this, what is the effective theory that describes the universe on large scales? In this paper we make progress in addressing these questions. We show that the effective theory for the long-wavelength universe behaves as a viscous fluid coupled to gravity: integrating out short-wavelength perturbations renormalizes the homogeneous background and introduces dissipative dynamics into the evolution of long-wavelength perturbations. The effective fluid has small perturbations and is characterized by a few parameters like an equation of state, a sound speed and a viscosity parameter. These parameters can be matched to numerical simulations or fitted from observations. We find that the backreaction of small-scale non-linearities is very small, being suppressed by the large hierarchy between the scale of non-linearities and the horizon scale. The effective pressure of the fluid is always positive and much too small to significantly affect the background evolution. Moreover, we prove that virialized scales decouple completely from the large-scale dynamics, at all orders in the post-Newtonian expansion. We propose that our effective theory be used to formulate a well-defined and controlled alternative to conventional perturbation theory, and we discuss possible observational applications. Finally, our way of reformulating results in second-order perturbation theory in terms of a long-wavelength effective fluid provides the opportunity to understand non-linear effects in a simple and physically intuitive way.Comment: 84 pages, 3 figure

Centrality Dependence Of The Pseudorapidity Density Distribution For Charged Particles In Pb-pb Collisions At √snn=2.76tev

7264/Mai61062

Long-range Angular Correlations On The Near And Away Side In P-pb Collisions At √snn=5.02 Tev

7191/Mar294

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362